The article describes the importance of using drugs that combine long-acting muscarinic receptor antagonists with long-acting beta2-agonists (LAMA/LABA) in the treatment of chronic obstructive pulmonary disease (COPD). A brief description of the disease and its epidemiology are presented. The mechanism of LAMA/LABA drugs are discussed. Based on the recommendations of GOLD 2017, indications for treatment with these bronchodilators were defined. The studies comparing the LAMA/LABA treatment with the LAMA or LABA monotherapy were cited. Various combinations have been listed together with clinical tests assessing their effectiveness. The article lists the difficulties for patients associated with drug inhalation. LAMA/LABA drugs are described from the perspective of medicine based on phenotyping patients and personalisation of treatment. Conclusions regarding possible additional therapy with inhaled corticosteroids (ICS) and the future of this group of drugs are presented.